InterventionsHumans

Real-World Outcomes of Tirzepatide Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Peripheral Arterial Disease

AHA Scientific Sessions 2025 Abstract

The paper

Thitiphan Srikulmontri, Suchanart Pantarote, Narathorn Kulthamrongsri,

Chanokporn Puchongmart, Panat Yanpiset, Phuuwadith Wattanachayakul,

Aman M. Amanullah

Jefferson Einstein Philadelphia Hospital

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4364028

doi.org/10.1161/circ.152.suppl_3.4364028

SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026